Allogene Therapeutics announced a leadership transition that will replace President and CEO David Chang with Zachary Roberts, Allogene’s current EVP of R&D and CMO. The company said Roberts will succeed Chang on July 1 and will also join the board. Chang, an Allogene co-founder, will remain on the board following the change. The move signals planned continuity in the off-the-shelf cell therapy company’s executive oversight while passing operational and strategic responsibilities to Roberts as it manages ongoing clinical and commercial build-out. Investors and clinicians will likely watch near-term updates tied to Roberts’ R&D focus and how leadership changes affect trial execution and partnering activity.